Probing binding modes of small molecule inhibitors to the polo-box domain of human polo-like kinase 1

ACS Medicinal Chemistry Letters

Volumn 1, Issue 3, 2010, Pages 110-114

  Liao, Chenzhong ^a   Park, Jung Eun ^b   Bang, Jeong K ^c   Nicklaus, Marc C ^a   Lee, Kyung S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

binding mode; cancer therapeutics; induced fit docking; polo box domain; Polo like kinase 1

Indexed keywords

CYSTEINE; ENZYME INHIBITOR; POLO LIKE KINASE 1; POLOXIN; PURPUROGALLIN; THYMOQUINONE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COVALENT BOND; DRUG BINDING; DRUG DESIGN; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; MOLECULAR DOCKING; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTEIN DOMAIN;

EID: 77956624673     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100020e     Document Type: Article

References (25)

1. Archambault, V.; Glover, D. M. Polo-like kinases: Conservation and divergence in their functions and regulation Nat. Rev. Mol. Cell. Biol. 2009, 10, 265-275
2. Strebhardt, K.; Ullrich, A. Targeting polo-like kinase 1 for cancer therapy Nat. Rev. Cancer 2006, 6, 321-330
3. Luo, J.; Emanuele, M. J.; Li, D.; Creighton, C. J.; Schlabach, M. R.; Westbrook, T. F.; Wong, K. K.; Elledge, S. J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 2009, 137, 835-848
4. Sur, S.; Pagliarini, R.; Bunz, F.; Rago, C.; Diaz, L. A., Jr.; Kinzler, K. W.; Vogelstein, B.; Papadopoulos, N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 Proc. Natl. Acad. Sci. 2009, 106, 3964-3969
5. Lee, K. S.; Idle, J. R. Pinning down the polo-box domain Chem. Biol. 2008, 15, 415-416
6. Watanabe, N.; Sekine, T.; Takagi, M.; Iwasaki, J.; Imamoto, N.; Kawasaki, H.; Osada, H. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition J. Biol. Chem. 2009, 284, 2344-2353
7. Reindl, W.; Yuan, J.; Kramer, A.; Strebhardt, K.; Berg, T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions Chem. Biol. 2008, 15, 459-466
8. Cheng, K. Y.; Lowe, E. D.; Sinclair, J.; Nigg, E. A.; Johnson, L. N. The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex EMBO J. 2003, 22, 5757-5768
9. Elia, A. E.; Rellos, P.; Haire, L. F.; Chao, J. W.; Ivins, F. J.; Hoepker, K.; Mohammad, D.; Cantley, L. C.; Smerdon, S. J.; Yaffe, M. B. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain Cell 2003, 115, 83-95
10. Garcia-Alvarez, B.; de Carcer, G.; Ibanez, S.; Bragado-Nilsson, E.; Montoya, G. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization Proc. Natl. Acad. Sci. 2007, 104, 3107-3112
11. Yun, S. M.; Moulaei, T.; Lim, D.; Bang, J. K.; Park, J. E.; Shenoy, S. R.; Liu, F.; Kang, Y. H.; Liao, C.; Soung, N. K.; Lee, S.; Yoon, D. Y.; Lim, Y.; Lee, D. H.; Otaka, A.; Appella, E.; McMahon, J. B.; Nicklaus, M. C.; Burke, T. R., Jr.; Yaffe, M. B.; Wlodawer, A.; Lee, K. S. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1 Nat. Struct. Mol. Biol. 2009, 16, 876-882
12. Kang, Y. H.; Park, J. E.; Yu, L. R.; Soung, N. K.; Yun, S. M.; Bang, J. K.; Seong, Y. S.; Yu, H.; Garfield, S.; Veenstra, T. D.; Lee, K. S. Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation Mol. Cell 2006, 24, 409-422
13. Schrödinger Suite 2009 Induced Fit Docking Protocol; Schrödinger, LLC: New York, NY, 2009.
14. Glide, version 5.5; Schrödinger, LLC: New York, NY, 2009.
15. Prime, version 2.1; Schrödinger, LLC: New York, NY, 2009.
16. ADME/Tox WEB. http://pharma-algorithms.com/webboxes/ (accessed January 19, 2010).
17. pKa Plugin ionization equilibrium partial charge distribution. http://www.chemaxon.com/product/pka.html (accessed January 19, 2010).
18. a values of pharmaceutical substances J. Chem. Inf. Model. 2009, 49, 2801-2812
19. Lenart, P.; Petronczki, M.; Steegmaier, M.; Di Fiore, B.; Lipp, J. J.; Hoffmann, M.; Rettig, W. J.; Kraut, N.; Peters, J. M. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 Curr. Biol. 2007, 17, 304-315
20. Lee, K. S.; Park, J. E.; Kang, Y. H.; Zimmerman, W.; Soung, N. K.; Seong, Y. S.; Kwak, S. J.; Erikson, R. L. Mechanisms of mammalian polo-like kinase 1 (Plk1) localization: Self- versus non-self-priming Cell Cycle 2008, 7, 141-145
21. Chalker, J. M.; Bernardes, G. J.; Lin, Y. A.; Davis, B. G. Chemical modification of proteins at cysteine: opportunities in chemistry and biology Chem. Asian J. 2009, 4, 630-640
22. Wissner, A.; Mansour, T. S. The development of HKI-272 and related compounds for the treatment of cancer Arch. Pharm. (Weinheim) 2008, 341, 465-477
23. SiteMap, version 2.3; Schrödinger, LLC: New York, NY, 2009.
24. Macromodel 9.7; Schrödinger, LLC: New York, NY, 2009.
25. Hanisch, A.; Wehner, A.; Nigg, E. A.; Sillje, H. H. Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting Mol. Biol. Cell 2006, 17, 448-459